KetoSwiss is a Swiss biotechnology start-up based in Basel, founded in 2017. With the mission of providing an effective solution to migraines (and other neurological diseases) without the side effects of classical pharma products, based on solid scientific research and inspired by evolution.
KetoSwiss has identified a novel migraine subgroup: Metabolic Migraine and have developed a preventative solution (MigraKet) targeting the root cause of these migraines. Achieving 3x greater migraine day reduction over gold standard treatment (in responders).Their lead product’s active substance is an endogenous metabolite – a ketone body, which can be used by the brain as an alternative fuel to glucose when glucose utilization or transport is compromised. In later stages of development, their portfolio can be extended to other neurological diseases characterized by metabolic dysfunction, such as Alzheimer’s Disease.
The company is currently raising a Series-A round of CHF 8.5m
The funds will cover US launch activities, further drug product development, regulatory approvals, preparatory activities for the EU launch, phase 2b migraine clinical trial and phase 2a depression trial.
Interested investors are kindly asked to contact the project team for further information.
Contact project teamTOPADUR Pharma AG, founded in 2015, is a Swiss clinical stage start-up. Founded by experienced scientists that combine several years of expertise in research and development in the pharmaceutical industry. The company focuses on developing and commercializing effective and safe therapies to treat aging-related diseases such as chronic wounds, diabetic retinopathy, age-related macular degeneration, pulmonary fibrosis, colorectal cancer and hair loss.
TOPADUR’s most advanced product, TOP-N53 is moving to clinical phase 2a. The compound was designed to increase local microcirculation and to induce the formation of new blood vessels. This should result in enabling the healing of chronic wounds.
The company is currently raising a Series C-2 CHF 20m.
The funds from the capital increase will be used mainly for the development of the following products: TOP-N53 Phase 2a trial /wound healing diabetic retinopathy colorectal cancer alopecia further development of the pipeline and IPO preparation.
IPO to Nasdaq stock exchange segment planned for 2023.
Interested investors are kindly asked to contact the project team for further information.
Contact project team1 million people a day are being diagnosed with one of the common sexually transmitted diseases (STD). Yet, the only improvements made to testing of STDs such as chlamydia or gonorrhoea is the invention of self-sampling tests, but this still needs to be posted to a lab and takes up to 7 days for a result.
In 2020, we all learned to take control of our health and make it increasingly homebound and digitally enabled. Testmate Health is building on these rapid shifts in behaviour by delivering an anonymous & convenient option for self-testing anywhere, anytime. This solution is based on a colorimetric assay for isothermal DNA amplification from urine and is integrated into a simple-to-use device.
Testmate Health’s rapid at home self-test provides results in minutes, not days, for the four common STDs (chlamydia, gonorrhoea, trichomoniasis & mycoplasma genitalium). Our test is supported by digital health and allows quick follow-up in the case of a positive test. Testmate’s solution encompasses the full customer journey from self-testing to result analysis.
Testmate Health continues to grow its patent portfolio and holds IP ownership for the method, sample preparation & device. The global market for STD diagnostics is projected to grow at a rate of 6.4% per annum to reach 9.1 billion USD in 2020.
http://testmatehealth.com/
Testmate Health, with their research partners, has been awarded CHF 1.2M in non-dilutive funding to develop smartphone compatible at home self-testing kits for sexually transmitted diseases.
The company successfully closed the Seed A financing round in 2021.
Interested investors are kindly asked to contact the project team for further information.
Contact project teamEMBION Technologies is an industrial biotechnology and green chemistry EPFL spin-off founded in 2016 and based in Switzerland. The company enables new solutions and innovation from industrial biomass such as grains, fungi, algae, and microbial cells. Its catalyst technology allows selective extraction of bioactive ingredients and valorizes lignocellulosic plant biomass into higher functional nutrition, fighting food waste while setting up circular business models.
The catalysts are fully recoverable for subsequent use and are protected with multiple granted patents and patent applications. EMBION applies its proprietary depolymerization technology to hydrolyze the natural, nutritional macromolecules found in plants, microorganisms, and other sources of nutrients into highly bioavailable oligomers in a targeted and efficient way.
EMBION has developed the first product and has key contracts with customers signed.
https://embiontech.com/
The company is raising Series A2 Round size of CHF 5m
The funds will be used to: Setup commercial manufacturing, Expand sales and marketing,Reinforce intellectual property, & Grow innovation pipeline
Interested investors are kindly asked to contact the project team for further information.
Contact project teamLS Instruments is a spin-off of ETH Zurich and the University of Fribourg. The company develops and distributes analytical instruments for the characterization of nanosystems. Their patented technology is based on the optical method of light scattering.
The novelty of the patented technology is that users no longer need to dilute the samples as heavily as before and can measure them undiluted as well as in their natural state. This increases the value of measurements, reduces sample consumption, and enables improved quality control along the product value chain. The technology is used in academic research as well as in development and quality control by industrial customers in the pharmaceutical, food, cosmetics, and specialty chemicals sectors.
Since its founding, the company has built a customer base of over 150 customers in more than 30 countries.
https://lsinstruments.ch/en/
The company successfully closed the Series A financing round in 2021.
Interested investors are kindly asked to contact the project team for further information.
Contact project team